Clinical Policy: Lifileucel (Amtagvi)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.598 alerts
Get alerted when Policy CP.PHAR.598 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-necessity coverage for lifileucel (Amtagvi), primarily for adults with unresectable or metastatic melanoma; applies to Commercial, HIM/ICHRA, and Medicaid lines of business.
The policy added FDA-label-based requirements for concomitant IL-2 therapy, a resectable lesion, exclusion of uveal or ocular melanoma, and restrictions for prior organ allograft, TIL therapy, or CAR-T therapy.
Prior authorization requests were redirected to Precision Drug Action Committee utilization management review.
FDA-labeling updates added requirements for concomitant interleukin-2 therapy, documentation of at least one resectable lesion, confirmation that melanoma is not of known uveal or ocular origin, and restrictions related to prior organ allograft, TIL therapy, or CAR-T therapy.
The ICHRA line of business was added during the 2026 annual review.
Prior authorization reviews were redirected to the Precision Drug Action Committee Utilization Management Review process.
The 2026 annual review added the ICHRA line of business.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.